Clinical trials: Post COVID-19 Syndrome
Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID
Paxlovid for Treatment of Long Covid
The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid.
- Trial name
- STOP-PASC (NCT05576662)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Stanford University
Post-COVID-19 Syndrome
Cognitive Rehabilitation in Post-COVID-19 Syndrome
The first aim of this study is to determine the feasibility of delivering CO-OP remotely to individuals experiencing cognitive impairments that limit everyday activities in post-COVID-19 syndrome (PCS).
- Trial name
- NCT06136871
- Testing
- CO-OP Procedures, Inactive Control Group
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Missouri-Columbia
Long COVID-19, Long COVID
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19…
- Trial name
- RECOVER-VITAL (NCT05965726)
- Testing
- Paxlovid, Ritonavir
- Where
- United States
- Volunteers
- 964 people
- Sponsor
- Kanecia Obie Zimmerman
Post-acute Covid-19 Syndrome
Homeopathic Treatment of Post-acute COVID-19 Syndrome
To determine whether an individually prescribed homeopathic medicine has an effect greater than a placebo and is a viable treatment option to improve fatigue and quality of life for patients suffering from the symptoms of…
- Trial name
- NCT05104749
- Testing
- Homeopathic Medication
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Southwest College of Naturopathic Medicine
Kidney Transplant Recipients, Liver Transplant Recipients
COVID Protection After Transplant-Immunosuppression Reduction
This study will enroll individuals who have: Completed primary series of mRNA COVID-19 vaccine, and An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
- Trial name
- CPAT-ISR (NCT05077254)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen
- Where
- 15 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
The primary objective of this study is to assess the feasibility and acceptability of methods and procedures to be employed in a larger scale decentralized platform adaptive randomized clinical trial in patients with a history of…
- Trial name
- NCT05946551
- Testing
- Cetirizine, Famotidine
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Long COVID, Long Covid19
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Trial name
- NCT05965739
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Long Covid19, Long COVID
Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms
This cross-over study will assess a no added sugar diet, a restricted daily eating window, and one or two full day water fasts to determine if there is an effect on self-reported symptoms of Long Covid (PASC).
- Trial name
- NCT06214455
- Testing
- Low sugar diet and 10-12 hour eating window, Low sugar diet, 8 hour eating window and fasting
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Pacific Northwest University of Health Sciences
Post COVID-19 Condition, Long COVID
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
- Trial name
- NCT05592418
- Testing
- Rintatolimod
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- AIM ImmunoTech Inc.